What are the treatment options for overactive bladder (OAB)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Introduction to Overactive Bladder (OAB) Treatment

Overactive bladder (OAB) is a highly prevalent condition that significantly impacts the quality of life of affected individuals. The management of OAB involves a stepwise approach, incorporating conservative measures, pharmacological interventions, and surgical options.

First-Line Treatment Options

First-line treatment for OAB includes:

  • Conservative measures such as weight reduction, decrease in exposure to bladder stimulants, fluid optimization, and pelvic floor exercises 1
  • Pharmacological treatments including anticholinergic medications like oxybutynin, and beta-3 agonists 2, 3, 4
  • Posterior tibial nerve stimulation procedures 2, 3

Second-Line Treatment Options

For patients who are unresponsive to first-line treatments, second-line options may be considered:

  • Onabotulinumtoxin-A (Onabot-A) bladder injections, which have been shown to be effective in reducing symptoms of OAB, but may be associated with higher rates of acute urinary retention and urinary tract infections 2, 4
  • Sacral nerve stimulation (SNS), which has been found to have similar efficacy to Onabot-A, but with different adverse event profiles 2

Third-Line Treatment Options

For patients who are refractory to first- and second-line treatments, third-line options may be considered:

  • Peripheral tibial nerve stimulation
  • Sacral nerve stimulation

Pharmacological Treatment

Pharmacological treatment for OAB includes:

  • Antimuscarinic agents, which can be effective in reducing symptoms of OAB, but may be associated with adverse events such as dry mouth and constipation 2, 4
  • Beta-3 adrenoceptor agonists, which have been shown to be effective in reducing symptoms of OAB, with a more favorable adverse event profile compared to antimuscarinic agents 2, 4
  • Combination therapy with antimuscarinic agents and beta-3 adrenoceptor agonists, which may be considered for patients with suboptimal response to monotherapy 4

Patient Education and Counseling

Patient education and counseling are essential components of OAB management, and should include information on:

  • Behavioral modification techniques
  • Available treatment options
  • Expected outcomes and potential adverse events associated with each treatment option 4, 5

Conclusion

The treatment of OAB requires a stepwise approach, incorporating conservative measures, pharmacological interventions, and surgical options. The choice of therapy should be guided by individual patient factors, and patients should be carefully monitored and counseled on available treatment options to optimize symptom control and set realistic expectations 2, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.